Related Experiment Video
Updated: Jul 1, 2026
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
SLIT2 as a key regulator and therapeutic target in liver injury
Yong Won Choi1, Jae Ho Choi2, Young-Sam Lee3
1Inflamm-Aging Translational Research Center, Ajou University Medical Center, Suwon 16499, Korea; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon 16499, Korea.
Abstract:
Drug-induced liver injury accounts for approximately 10% of acute hepatitis and up to 50% of acute liver failure. Despite its clinical significance, treatment remains largely limited to cessation of the offending agent. SLIT/ROBO signaling, known for roles in organ development, angiogenesis, leukocyte migration, and cancer metastasis, has demonstrated protective effects against various organ damage. In mouse models of liver injury induced by acetaminophen (APAP), thioacetamide, bile duct ligation, and serum from patients with toxic liver disease, Slit2 expression significantly increases, while Slit1 and Slit3 remain unchanged. Liver-specific Slit2 knockdown exacerbates liver injury, whereas recombinant SLIT2 alleviates liver damage by reducing oxidative stress via CYP2E1 downregulation and suppressing inflammation through nuclear factor κB inhibition. Notably, among ROBO receptors, only ROBO4 was induced in hepatocytes after APAP exposure. ROBO4 knockdown eliminates the hepatoprotective effects of SLIT2, highlighting the importance of SLIT2/BOBO4 signaling in toxic liver injury. Furthermore, the novel Slit2-derived peptide 5 (SP5), designed from the ROBO4-binding LRR2 domain, significantly reduces liver damage and inflammation. Notably, both recombinant SLIT2 and SP5 confer hepatoprotection even when administered 24 h after APAP challenge. These findings suggest that SLIT2/ROBO4-targeted therapies may offer a promising approach for preventing fulminant hepatitis in the context of toxic liver injury.
Insights
Drug-induced liver injury is a serious condition. The study found that SLIT2/ROBO4 signaling protects the liver from damage and inflammation, offering potential new therapies for toxic liver injury.
Area of Science:
- Hepatology
- Molecular Biology
- Immunology
Background:
- Drug-induced liver injury (DILI) is a major cause of acute hepatitis and liver failure.
- Current treatments for DILI are limited to discontinuing the causative agent.
- SLIT/ROBO signaling pathways are implicated in various physiological processes and organ protection.
Purpose of the Study:
- To investigate the role of SLIT/ROBO signaling in DILI.
- To explore the therapeutic potential of targeting SLIT2/ROBO4 in liver injury.
Main Methods:
- Utilized mouse models of DILI induced by acetaminophen (APAP), thioacetamide, bile duct ligation, and patient serum.
- Assessed changes in Slit1, Slit2, and Slit3 expression.
- Investigated the effects of liver-specific Slit2 knockdown and recombinant SLIT2 administration.
- Examined the role of ROBO receptors, particularly ROBO4, in SLIT2-mediated protection.
- Evaluated a novel Slit2-derived peptide-5 (SP5).
Main Results:
- Slit2 expression significantly increased in DILI mouse models, while Slit1 and Slit3 remained unchanged.
- Liver-specific Slit2 knockdown worsened DILI.
- Recombinant SLIT2 reduced liver damage by decreasing oxidative stress (via CYP2E1 downregulation) and inflammation (via NF-κB inhibition).
- ROBO4 was induced in hepatocytes post-APAP exposure, and its knockdown abolished SLIT2's protective effects.
- SP5 demonstrated significant hepatoprotection and reduced inflammation.
- Both recombinant SLIT2 and SP5 provided protection even when administered 24 hours after APAP challenge.
Conclusions:
- SLIT2/ROBO4 signaling plays a critical protective role in toxic liver injury.
- Targeting SLIT2/ROBO4 pathways, including with novel peptides like SP5, represents a promising therapeutic strategy for DILI and fulminant hepatitis.
